Arecor Therapeutics PLC published interim results for the six months to 30 June 2026 on 30 September 2026 and announced, the same day, a proposed fundraising of up to £5.13m. A retail offer followed and its result was announced on 7 October, and on 15 October the company published an update on patents for concentrated ultra-rapid insulins. The company is listed on AIM and is a constituent of the FTSE AIM All Share Index.

According to a summary of the interim results, Revenue was £0.2m against £1.0m a year earlier, Research and Development costs rose to £1.9m from £1.3m, and the loss after tax widened to £3.0m from £2.0m. Cash was £3.2m, up from £1.9m. The figures come from an AI-generated summary and should be checked against the full release.

What Arecor does

Arecor is a Drug Development company. The summary points to two areas of activity: an insulin and automated insulin delivery combination, where it cites term sheet stage partnering discussions, and AT278, a programme in co-development.

The fundraising

A proposed fundraising was announced on 30 September, followed by a placing result and a close of the accelerated bookbuild the same day. A retail offer to raise up to £130,000 was announced on 30 September, and its result on 7 October. The share price and the total raised are not given here. Several holdings-in-company notices followed between 7 and 13 October, which typically record changes in large shareholdings.

Pipeline news

On 13 August 2026 the company announced that AT278 data had been published in a peer-reviewed journal, and on 15 October it announced patents for concentrated ultra-rapid insulins. No claim is made here about their commercial value.

Dividend picture

No Dividend was mentioned in the announcements, and a loss-making development company would not be expected to pay one.

Sector and index context

Biotechnology companies at this stage depend on partnerships, licensing income and Equity raisings, and revenue can be lumpy, as the fall from £1.0m to £0.2m suggests. Diabetes treatment is a large market, but competition and regulation are demanding.

Key risks

The main risks are further funding needs, dilution for existing shareholders, the possibility that partnering talks do not produce a signed agreement, and trial or regulatory setbacks.

What to watch next

Investors will watch for a signed Partnership on the insulin and delivery combination, progress on AT278 co-development, how the company deploys its fresh funds, and the next trading update.

Why funding rounds follow results

It is common for small drug developers to announce a fundraising alongside or shortly after results, when the numbers are public and the company has no undisclosed information. A placing with institutions, plus a small offer to retail investors, is a typical structure on AIM, allowing existing shareholders to take part. The cost is dilution, because new shares are issued. Cash of £3.2m against a half-year loss of £3.0m shows why additional money was sought, though the amount raised should be confirmed from the announcements. Investors in the sector also tend to focus on how many months of spending the available cash can cover.

Patent announcements are another signal. Intellectual property is central to the value of a drug delivery or formulation company, but patents alone do not determine commercial success. Because the company has just raised money, its cash position as of today is likely to differ from the £3.2m reported at 30 June, and the full announcements should be checked for the figures.